PDCD1 and infantile convulsions and choreoathetosis: Together, the findings indicate that in GOLP treatment, the chemotherapy can rectify aberrant cell proliferation, lenvatinib can rectify abnormal angiogenesis and KIT signaling, and the anti-PD1 antibody can reverse the suppressive immune status, thus benefiting iCCA patients with high levels of these molecular features.